(Q36898852)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17668418%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Refining basal insulin therapy: what have we learned in the age of analogues? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17668418%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17668418%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Nattrass M

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17668418%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Pieber TR

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17668418%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

1 reference

1 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17668418%20AND%20SRC:MED&resulttype=core&format=json

Diabetes - Metabolism: Research and Reviews

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17668418%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17668418%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17668418%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

441-454

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17668418%20AND%20SRC:MED&resulttype=core&format=json

Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus

2 January 2020

cites work

1 reference

Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes

21 January 2018

1 reference

Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine

21 January 2018

1 reference

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

21 January 2018

1 reference

Contributions of fasting and postprandial glucose to hemoglobin A1c.

21 January 2018

1 reference

21 January 2018

1 reference

7 January 2021

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

1 reference

7 January 2021

Hypoglycemia as a barrier to glycemic control

1 reference

7 January 2021

New insulins in the treatment of diabetes mellitus

1 reference

7 January 2021

1 reference

7 January 2021

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

1 reference

7 January 2021

Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

1 reference

7 January 2021

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

7 January 2021

Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers.

1 reference

7 January 2021

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

7 January 2021

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

1 reference

7 January 2021

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

1 reference

7 January 2021

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

1 reference

7 January 2021

Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens

1 reference

7 January 2021

Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes

1 reference

7 January 2021

Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin

1 reference

7 January 2021

Does insulin detemir have a role in reducing risk of insulin-associated weight gain?

1 reference

7 January 2021

Invasiveness as a barrier to self-monitoring of blood glucose in diabetes

1 reference

7 January 2021

Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study.

1 reference

7 January 2021

Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

1 reference

7 January 2021

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

1 reference

7 January 2021

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

1 reference

7 January 2021

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

7 January 2021

A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes

1 reference

7 January 2021

A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes

1 reference

7 January 2021

Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart

1 reference

7 January 2021

Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy

1 reference

7 January 2021

Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine

1 reference

7 January 2021

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

1 reference

7 January 2021

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

7 January 2021

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

7 January 2021

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

1 reference

7 January 2021

Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility

1 reference

7 January 2021

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

1 reference

7 January 2021

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

1 reference

7 January 2021

Evening insulin strategy

1 reference

7 January 2021

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

1 reference

7 January 2021

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

1 reference

7 January 2021

Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial

1 reference

7 January 2021

Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times

1 reference

7 January 2021

Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy

1 reference

7 January 2021

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

1 reference

7 January 2021

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

1 reference

7 January 2021

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

1 reference

7 January 2021

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

1 reference

7 January 2021

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

1 reference

7 January 2021

A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study

1 reference

7 January 2021

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

7 January 2021

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

1 reference

7 January 2021

Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.762

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17668418%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference